SCHEMBL6890552

SCHEMBL6890552

CCc1nc2ccc(N3CCN4CCC3CC4)cc2c(=O)n1CC1CCOCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.40
CNR2 P34972 3/20 0.39
TLR7 Q9NYK1 2/20 0.39
BRD4 O60885 2/20 0.39
PDE1A P54750 3/20 0.38
PDE1B Q01064 3/20 0.38
PDE1C Q14123 3/20 0.38
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
PDE5A O76074 1/20 0.36
BAZ2A Q9UIF9 1/20 0.35
HIF1A Q16665 1/20 0.35
ENPP2 Q13822 1/20 0.35
HTR3A P46098 1/20 0.35
KCNH2 Q12809 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887450 0.93 CHRNA7 (0.43) CHRNA7CNR2HTR3AKCNH2
SCHEMBL6888096 0.84 CHRNA7 (0.44) CHRNA7ALDH1A1KDM4EHPGDCYP1A2
SCHEMBL6887544 0.83 CHRNA7 (0.43) CHRNA7ALDH1A1KCNH2SMN1; SMN2
SCHEMBL6887861 0.81 CHRNA7 (0.46) CHRNA7HTR3AKCNH2
SCHEMBL6888452 0.80 AVPR1A (0.46)
SCHEMBL6888588 0.80 CHRNA7 (0.40) CHRNA7TLR7ALDH1A1ENPP2KCNH2
SCHEMBL6888343 0.80 CHRNA7 (0.40) CHRNA7HTR3AKCNH2
SCHEMBL6887453 0.79 CHRNA7 (0.44) CHRNA7CNR2KDM4EHPGDHTR3A
SCHEMBL6889309 0.79 CHRNA7 (0.44) CHRNA7HTR3AKCNH2SMN1; SMN2NPSR1
SCHEMBL6887911 0.78 AVPR1B (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 CHRNA7 3/4885CNR2 33/4885TLR7 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.